Agendia to Seek Expanded MammaPrint Clearance for Older Patients | GenomeWeb
NEW YORK (GenomeWeb News) – Agendia said yesterday that it plans to seek expanded clearance from the US Food and Drug Administration for the use of its MammaPrint breast cancer prognosis test in patients over the age of 60.
 
The Amsterdam-based company said it has completed a study that has shown the test to be useful in assessing the risk of the recurrence of breast cancer in older, post-menopausal patients.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.

Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.

In Nature this week: genomic analysis of prehistoric New Mexicans, a nanopore method for mapping DNA methylation, and more.

A new study finds that adding missing good bacteria to the skin microbiome of atopic dermatitis patients decreases Staphylococcus aureus colonization.